Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair M Thompson

Showing results (1-10 of 195) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2014
Molecular pathways: preclinical models and clinical trials with metformin in breast cancerAlastair M Thompson
Current Opinion in Oncology|September 11, 2012
New standards of care in the management of the axillaAlastair M Thompson
Pharmacogenomics|April 21, 2012
The importance of nonpharmacogenetic factors in endocrine therapyColin McCowan, Alastair M Thompson
The Journal of Pathology|January 2, 2010
p53 transcriptional pathways in breast cancer: the good, the bad and the complexAlastair M Thompson, David P Lane
Breast (Edinburgh, Scotland)|May 6, 2006
Cyclin D1 and breast cancerPankaj G Roy, Alastair M Thompson
Breast Cancer Research : BCR|May 26, 2010
At last, a predictive and prognostic marker for radiotherapy?Philip Coates, John Dewar, Alastair M Thompson
British Journal of Cancer|June 28, 2022
Is loss of p53 a driver of ductal carcinoma in situ progression?Rhiannon L Morrissey, Alastair M Thompson, Guillermina Lozano
Surgical Oncology Clinics of North America|November 15, 2017
Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?Kelly J Rosso, Anna Weiss, Alastair M Thompson
Critical Reviews in Oncology/Hematology|March 18, 2008
Targeting AMPK: a new therapeutic opportunity in breast cancerSirwan M Hadad, Stewart Fleming, Alastair M Thompson
Virchows Archiv : an International Journal of Pathology|August 27, 2021
Low-risk DCIS. What is it? Observe or excise?Sarah E Pinder, Alastair M Thompson, Jelle Wesserling
Pageof 20

Showing results (1-10 of 195) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2014
Molecular pathways: preclinical models and clinical trials with metformin in breast cancerAlastair M Thompson
Current Opinion in Oncology|September 11, 2012
New standards of care in the management of the axillaAlastair M Thompson
Pharmacogenomics|April 21, 2012
The importance of nonpharmacogenetic factors in endocrine therapyColin McCowan, Alastair M Thompson
The Journal of Pathology|January 2, 2010
p53 transcriptional pathways in breast cancer: the good, the bad and the complexAlastair M Thompson, David P Lane
Breast (Edinburgh, Scotland)|May 6, 2006
Cyclin D1 and breast cancerPankaj G Roy, Alastair M Thompson
Breast Cancer Research : BCR|May 26, 2010
At last, a predictive and prognostic marker for radiotherapy?Philip Coates, John Dewar, Alastair M Thompson
British Journal of Cancer|June 28, 2022
Is loss of p53 a driver of ductal carcinoma in situ progression?Rhiannon L Morrissey, Alastair M Thompson, Guillermina Lozano
Surgical Oncology Clinics of North America|November 15, 2017
Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?Kelly J Rosso, Anna Weiss, Alastair M Thompson
Critical Reviews in Oncology/Hematology|March 18, 2008
Targeting AMPK: a new therapeutic opportunity in breast cancerSirwan M Hadad, Stewart Fleming, Alastair M Thompson
Virchows Archiv : an International Journal of Pathology|August 27, 2021
Low-risk DCIS. What is it? Observe or excise?Sarah E Pinder, Alastair M Thompson, Jelle Wesserling
Pageof 20